nach oben

Lasers in Medical Science

Erschienen in:

01.12.2023 | Original Article

A study of the objective benefits and safety of Er-YAG laser in the treatment of genitourinary syndrome of menopause

verfasst von: Zerrin Avul, Cenk Mustafa Guven

Erschienen in: Lasers in Medical Science | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to evaluate changes in vaginal pH and epithelium maturation after erbium-doped yttrium aluminum garnet (Er-YAG) laser treatment, and to assess its safety and efficacy on the symptoms of genitourinary syndrome of menopause (GSM). This was a retrospective study conducted between November 2019 and April 2022 and included 32 women diagnosed with GSM who had not benefitted from lubrication treatment and could not or would not use estrogen. Patients received three sessions of Er- YAG laser. All patient data before and after treatment were obtained from computer records. Vaginal maturation index (VMI), maturation value (MV) and vaginal pH values of the patients before and after laser treatment were compared. We also evaluated post-procedural complications and symptoms. Mean age was 59.72 ± 5.66 years. After laser therapy, there was a significant decrease in vaginal pH (p < 0.001) and the proportion of parabasal cells in VMI (p < 0.001), while there was a significant increase in MV (p < 0.001) and the proportion of superficial cells in VMI (p < 0.001). In 84.4% of the patients, GSM-related symptoms regressed completely or decreased to a tolerable level. Patients in which symptoms disappeared completely had significantly lower mean age (p = 0.002) and duration of menopause (p = 0.009). The laser procedure resulted in complications including mucosal injury in 5 (15.6%) patients (all recovered spontaneously) and vaginal burning sensation in 2 (6.3%) patients. Vaginal Er-YAG laser treatment may be a safe and effective alternative treatment method in a population of women with GSM who do not want to or cannot use estrogen therapy.

Nur mit Berechtigung zugänglich

Da Silva AS, Baines G, Araklitis G, Robinson D, Cardozo L (2021) Modern management of genitourinary syndrome of menopause. Fac Rev 10:25. https://doi.org/10.12703/r/10-25CrossRefPubMedPubMedCentral

Mothes AR, Runnebaum M, Runnebaum IB (2018) An innovative dual-phase protocol for pulsed ablative vaginal Erbium:YAG laser treatment of urogynecological symptoms. Eur J Obstet Gynecol Reprod Biol 229:167–171. https://doi.org/10.1016/j.ejogrb.2018.08.010CrossRefPubMed

Mothes AR, Runnebaum M, Runnebaum IB (2018) Ablative dual-phase Erbium:YAG laser treatment of atrophy-related vaginal symptoms in post-menopausal breast cancer survivors omitting hormonal treatment. J Cancer Res Clin Oncol 144:955–960. https://doi.org/10.1007/s00432-018-2614-8CrossRefPubMed

Gaspar A, Maestri S, Silva J, Brandi H, Luque D, Koron N, Vižintin Z (2018) Intraurethral Erbium:YAG laser for the management of urinary symptoms of genitourinary syndrome of menopause: A pilot study. Lasers Surg Med 50:802–807. https://doi.org/10.1002/lsm.22826CrossRefPubMedPubMedCentral

Gambacciani M, Levancini M, Cervigni M (2015) Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause. Climacteric 18:757–763. https://doi.org/10.3109/13697137.2015.1045485CrossRefPubMedPubMedCentral

Gaspar A, Brandi H, Gomez V, Luque D (2017) Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Lasers Surg Med 49:160–168. https://doi.org/10.1002/lsm.22569CrossRefPubMed

Moral E, Delgado JL, Carmona F, Caballero B, Guillán C, González PM, Suárez-Almarza J, Velasco-Ortega S, Nieto C (2018) Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric 21:167–173. https://doi.org/10.1080/13697137.2017.1421921CrossRefPubMed

Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, Khan SA (2016) Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol 215:704–711. https://doi.org/10.1016/j.ajog.2016.07.045CrossRefPubMed

Filippini M, Luvero D, Salvatore S, Pieralli A, Montera R, Plotti F, Candiani M, Angioli R (2020) Efficacy of fractional CO2 laser treatment in postmenopausal women with genitourinary syndrome: a multicenter study. Menopause 27:43–49. https://doi.org/10.1097/gme.0000000000001428CrossRefPubMed

10.

Politano CA, Costa-Paiva L, Aguiar LB, Machado HC, Baccaro LF (2019) Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial. Menopause 26:833–840. https://doi.org/10.1097/gme.0000000000001333CrossRefPubMed

11.

Paraiso MFR, Ferrando CA, Sokol ER, Rardin CR, Matthews CA, Karram MM, Iglesia CB (2020) A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial. Menopause 27:50–56. https://doi.org/10.1097/gme.0000000000001416CrossRefPubMed

12.

Mension E, Alonso I, Tortajada M, Matas I, Gómez S, Ribera L, Anglès S, Castelo-Branco C (2022) Vaginal laser therapy for genitourinary syndrome of menopause - systematic review. Maturitas 156:37–59. https://doi.org/10.1016/j.maturitas.2021.06.005CrossRefPubMed

13.

Bojanini JF (2016) Treatment of genitourinary syndrome of menopause with Erbium: YAG laser: a prospective study of efficacy and safety of the treatment for women after menopause of natural origin and therapy-induced menopause in breast cancer survivors. J Laser Health Acad 2016:35–40

14.

Gambacciani M, Albertin E, Torelli MG, Bracco GL, Casagrande AC, Martella L, Baiocchi G, Alfieri S, Russo N, Cervigni M (2020) Sexual function after vaginal erbium laser: the results of a large, multicentric, prospective study. Climacteric 23:S24-s27. https://doi.org/10.1080/13697137.2020.1804544CrossRefPubMed

15.

Arêas F, Valadares ALR, Conde DM, Costa-Paiva L (2019) The effect of vaginal erbium laser treatment on sexual function and vaginal health in women with a history of breast cancer and symptoms of the genitourinary syndrome of menopause: a prospective study. Menopause 26:1052–1058. https://doi.org/10.1097/gme.0000000000001353CrossRefPubMed

16.

Singwongsa A, Vallibhakara O (2019) The effect of vaginal Erbium-YAG laser treatment for the genitourinary syndrome of menopause: a randomized controlled study. Maturitas 124:153–154. https://doi.org/10.1016/j.maturitas.2019.04.124CrossRef

17.

Lima S, Honorato JV (2019) Critical analysis of methods for assessing genitourinary syndrome of menopause used in clinical trials. Menopause 26:1436–1442. https://doi.org/10.1097/gme.0000000000001406CrossRefPubMed

18.

Gaspar A, Silva J, Calderon A, Di Placido V, Vizintin Z (2020) Histological findings after non-ablative Er:YAG laser therapy in women with severe vaginal atrophy. Climacteric 23:S11–S13. https://doi.org/10.1080/13697137.2020.1764525CrossRefPubMed

19.

Tucker KM, Godha K, Mirkin S, Archer DF (2018) Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal women. Menopause 25:762–766. https://doi.org/10.1097/gme.0000000000001081CrossRefPubMed

20.

Lumbanraja IL, Siregar M, Lumbanraja SN, Adenin I, Lintang LS, Halim B (2021) Association of vaginal maturation index and vaginal pH with the most bothersome symptoms of genitourinary syndrome of menopause. South Asian Fed Obstet Gynecol 13:288–291

21.

Lindau ST, Dude A, Gavrilova N, Hoffmann JN, Schumm LP, Mcclintock MK (2017) Prevalence and correlates of vaginal estrogenization in postmenopausal women in the United States. Menopause 24:536–545. https://doi.org/10.1097/gme.0000000000000787CrossRefPubMedPubMedCentral

22.

Meisels A (1967) The maturation value. Acta Cytol 11:249PubMed

23.

Johnston SL, Farrell SA, Bouchard C, Farrell SA, Beckerson LA, Comeau M, Johnston SL, Lefebvre G, Papaioannou A (2004) The detection and management of vaginal atrophy. J Obstet Gynaecol Can 26:503–515. https://doi.org/10.1016/s1701-2163(16)30662-4CrossRefPubMed

24.

Mac Bride MB, Rhodes DJ, Shuster LT (2010) Vulvovaginal atrophy. Mayo Clin Proc 85:87–94. https://doi.org/10.4065/mcp.2009.0413CrossRefPubMedPubMedCentral

25.

Gambacciani M, Palacios S (2017) Laser therapy for the restoration of vaginal function. Maturitas 99:10–15. https://doi.org/10.1016/j.maturitas.2017.01.012CrossRefPubMed

26.

Lang P, Dell JR, Rosen L, Weiss P, Karram M (2017) Fractional CO(2) laser of the vagina for genitourinary syndrome of menopause: Is the out-of-pocket cost worth the outcome of treatment? Lasers Surg Med 49:882–885. https://doi.org/10.1002/lsm.22713CrossRefPubMed

27.

Gambacciani M, Levancini M, Russo E, Vacca L, Simoncini T, Cervigni M (2018) Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. Climacteric 21:148–152. https://doi.org/10.1080/13697137.2018.1436538CrossRefPubMed

28.

Dutra P, Heinke T, Pinho SC, Focchi GRA, Tso FK, De Almeida BC, Silva I, Speck NMG (2021) Comparison of topical fractional CO2 laser and vaginal estrogen for the treatment of genitourinary syndrome in postmenopausal women: a randomized controlled trial. Menopause 28:756–763. https://doi.org/10.1097/gme.0000000000001797CrossRefPubMed

29.

Sturdee DW, Panay N (2010) Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13:509–522. https://doi.org/10.3109/13697137.2010.522875CrossRefPubMed

30.

Gordon C, Gonzales S, Krychman ML (2019) Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy. Menopause 26:423–427. https://doi.org/10.1097/gme.0000000000001293CrossRefPubMed

31.

Drnovsek-Olup B, Beltram M, Pizem J (2004) Repetitive Er:YAG laser irradiation of human skin: a histological evaluation. Lasers Surg Med 35:146–151. https://doi.org/10.1002/lsm.20080CrossRefPubMed

32.

Zerbinati N, Serati M, Origoni M, Candiani M, Iannitti T, Salvatore S, Marotta F, Calligaro A (2015) Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci 30:429–436. https://doi.org/10.1007/s10103-014-1677-2CrossRefPubMed

33.

Goldstein I (2010) Recognizing and treating urogenital atrophy in postmenopausal women. J Womens Health (Larchmt) 19:425–432. https://doi.org/10.1089/jwh.2009.1384CrossRefPubMed

34.

Carranza-Lira S, Fragoso-Díaz N, Macgregor-Gooch AL, Garduño-Hernández MP, Ríos-Calderón K, Aparicio H (2003) Vaginal dryness assessment in postmenopausal women using pH test strip. Maturitas 45:55–58. https://doi.org/10.1016/s0378-5122(03)00082-3CrossRefPubMed

Titel: A study of the objective benefits and safety of Er-YAG laser in the treatment of genitourinary syndrome of menopause
verfasst von: Zerrin Avul
Cenk Mustafa Guven
Publikationsdatum: 01.12.2023
Verlag: Springer London
Erschienen in: Lasers in Medical Science / Ausgabe 1/2023
Print ISSN: 0268-8921
Elektronische ISSN: 1435-604X
DOI: https://doi.org/10.1007/s10103-023-03798-y

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

A study of the objective benefits and safety of Er-YAG laser in the treatment of genitourinary syndrome of menopause

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Correction to: In vitro effect of low-level laser therapy on the proliferative, apoptosis modulation, and oxi-inflammatory markers of premature-senescent hydrogen peroxide-induced dermal fibroblasts

The quantitative analysis of low-concentration (2%) ALA-PDT assisted with Q-switch 1064-nm Nd:YAG laser for acne vulgaris treatment

Efficacy of laser in re-osseointegration of dental implants—a systematic review

Targetoid CO2 laser resurfacing: a novel and safe technique to treat ice-pick and boxcar acne scars

Evaluation of photobiomodulation effect on cesarean-sectioned wound healing: a clinical study

Correction to: Pulsed transcranial photobiomodulation generates distinct beneficial neurocognitive effects compared with continuous wave transcranial light